The role of opioid system and its interaction with sympathetic nervous system in the processing of polycystic ovary syndrome modeling in rat

Archives of Gynecology and Obstetrics

Volumn 283, Issue 4, 2011, Pages 885-892

  Zangeneh, Farideh Zafari ^a   Mohammadi, A ^b   Ejtemaeimehr, Sh ^a   Naghizadeh, Mohammad Mahdi ^c   Fatemeh, Aminee ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c FASA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Clonidine; Nalterxone; Polycystic ovary syndrome (PCO); Rat; Yohimbine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CLONIDINE; ESTRADIOL; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; NALTREXONE; OPIATE RECEPTOR; STEROID; YOHIMBINE;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS LUTEUM; ESTRUS; FEMALE; GONADOTROPIN BLOOD LEVEL; HISTOLOGY; NONHUMAN; OUTCOME ASSESSMENT; OVARY FOLLICLE ATRESIA; OVARY POLYCYSTIC DISEASE; OVULATION; QUALITATIVE ANALYSIS; RAT; STEROID BLOOD LEVEL;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ANIMALS; CLONIDINE; DISEASE MODELS, ANIMAL; ESTRADIOL; FEMALE; GONADAL STEROID HORMONES; NALTREXONE; NARCOTIC ANTAGONISTS; OVARY; POLYCYSTIC OVARY SYNDROME; RATS; RATS, WISTAR; RECEPTORS, OPIOID; SYMPATHETIC NERVOUS SYSTEM; YOHIMBINE;

EID: 79955936962     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-010-1776-7     Document Type: Article

References (48)

1. Stein IF, Leventhal ML (1953) Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29:181-191
2. Goldzieher JW (1981) Polycystic ovarian disease. Fertil Steril 35:371-394
3. Mallappa Saroja CS, Hanji Chandrashekar S (2010) Polycystic ovaries: review of medical information on the internet for patients. Arch Gynecol Obstet 281:839-843
4. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA (1992) Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 67:1807-1812
5. Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165-169 (Pubitemid 29036695)
6. DeUgarte CM, Bartolucci AA, Azziz R (2005) Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 83:1454-1460 (Pubitemid 40615820)
7. Solomon CG (2003) Reducing cardiovascular risk in type 2 diabetes. N Engl J Med 348:457-459
8. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L (2003) Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. J Metabol 52:908-915 (Pubitemid 36957780)
9. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929-1935 (Pubitemid 40586223)
10. Sam S, Legro RS, Bentley-Lewis R, Dunaif A (2005) Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:4797-4802 (Pubitemid 41159374)
11. Eagleson CA, Marshall JC (1999) Neuroendocrine aspects of polycystic ovary syndrome. Endocrinol Metab Clin North Am 28:295-324 (Pubitemid 29242715)
12. Solomon CG (1999) The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol Metab Clin North Am 28:247-263
13. Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS (2001) The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 86:5925-5933 (Pubitemid 33152646)
14. Aguado LI (2002) Role of the central and peripheral nervous system in the ovarian function. J Microsc Res Tech 59:462-473
15. Sverrisdottir YB, Mogrent T, Kataoka J, Janson PO, Stener-Victorin E (2008) Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? Am J Physiol Endocrinol Metab 294:E576-E581
16. Eyvazzadeh AD, Pennington KP, Pop-Busui R, Sowers M, Zubieta JK, Smith YR (2009) The role of the endogenous opioid system in polycystic ovary syndrome. Fertil Steril 92:1-12
17. Andersson s, Lundeberg T (1995) Acupuncture - from empiricism to science: functional background to acupuncture effects in pain and disease. Med Hypotheses 45:271-281
18. Fulghesu AM, Ciampelli M, Belosi C, Apa R, Guido M, Caruso A (2001) Naltrexone effects on pulsatile GnRH therapy for ovulation induction in PCOS: a pilot prospective study. J Endocrinol Invest 24:483-490
19. Ahmed MI, Duleba AJ, El Shahat O, Ibrahim ME, Salem A (2008) Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome. Hum Reprod 23:2564-2569
20. Ciampelli M, Fulghesu AM, Guido M, Murgia F, Muzj G, Belosi C, Fortini A, Cento R, Lanzone A (1998) Opioid blockade effect on insulin beta-cells secretory patterns in polycystic ovary syndrome Oral glucose load versus intravenous glucagon bolus. Horm Res 49:263-268 (Pubitemid 28241086)
21. Gabriel SM, Berglund LA, Simpkins JW (1986) A decline in endogenous opioid influence during the steroid-induced hypersecretion of luteinizing hormone in the rat. J Endocrin 118:558-561 (Pubitemid 16162771)
22. Fulghesu AM, Ciampelli M, Guido M, Murgia F, Caruso A, Mancuso S, Lanzone A (1998) Role of opioid tone in the pathophysiology of hyperinsulinemia and insulin resistance in polycystic ovarian disease. Metabolism 47:158-162 (Pubitemid 28084149)
23. Wortsman J, Wehrenberg WB, Gavin JR, Allen JP (1984) Elevated levels of plasma betaendorphin and melanocyte stimulating hormone in the polycystic ovary syndrome. Obstet Gynecol 63:630-635
24. Fulghesu AM, Lanzone A, Cucinelli F, Caruso A, Mancuso S (1993) Long-term naltrexone treatment reduces the exaggerated insulin secretion in patients with polycystic ovary disease. Obstet Gynecol 82:191-197 (Pubitemid 23217657)
25. Lanzone A, Fulghesu AM, Fortini A, Cutillo G, Cucinelli F, Di Simone N (1991) Effect of opiate receptor blockade on the insulin response to oral glucose load in polycystic ovarian disease. Hum Reprod 6:1043-1049
26. Angelopoulos TS, Deny BS, Weikart C, Dasilvas SG, Mickael TG, Robertson RJ (1995) Endogenous opioids may modulate cathecolamine secretion during high intensity exercise. Eur J Appl Physiol Occup Physiol 70:195-199
27. Hadziomerovic D, Rabenbauer B, Wildt l (2006) Normalization of hyperinsulinemia by chronic opioid receptor blockade in hyperandrogenemic women. Fertil Steril 86:651-657 (Pubitemid 44307010)
28. Brawer JR, Munoz M (1996) Development of the polycystic ovarian conditions (PCO) in the estradiol valerate-treated rat. Biol Reprod J 35:647-655
29. Genazzani AR, Genazzani AD, Volpogni C, Pianazzi F, Li GA, Surico N, Petraglia F (1993) Opioid control of gonadotrophin secretion in humans. Hum Reprod 8(Suppl 2):151-153 (Pubitemid 23337196)
30. Jenkins PJ, Grossman A (1993) The control of the gonadotrophin releasing hormone pulse generator in relation to opioid and nutritional cues. Hum Reprod 8(Suppl 2):154-161 (Pubitemid 23337197)
31. Dissen GA, Garcia-Rudaz C, Ojeda SR (2009) Role of neurotrophic factors in early ovarian development. Semin Reprod Med 27:24-31
32. Fagius J (2003) Sympathetic nerve activity in metabolic control-some basic concepts. Acta Physiol Scand 177:337-343
33. Ojeda S, Lara H (1989) Role of the sympathetic nervous system in the regulation of ovarian function. Springer, Berlin, pp 26-33
34. Reaven GM, Landsberg L, Lithell H (1996) Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334:374-381 (Pubitemid 26049592)
35. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Perez-Bravo F, Recabarren SE (2002) Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod 17:2573-2579 (Pubitemid 35174106)
36. Barria A, Leyton V, Ojeda SR, Lara HE (1993) Ovarian steroidal response to gonadotropins and beta-adrenergic stimulation is enhanced in polycystic ovary syndrome: role of sympathetic innervation. Endocrinology 133:2696-2703 (Pubitemid 24000722)
37. Manni L, Lundeberg T, Holmang A, Aloe L, Stener-Victorin E (2005) Effect of electro-acupuncture on ovarian expression of alpha (1)- and beta (2)-adrenoceptors, and p75 neurotrophin receptors in rats with steroid-induced polycystic ovaries. Reprod Biol Endocrinol 3:21
38. Desjardins GC, Beaudet A, Brawer JR (1990) Alterations in opioid parameters in the hypothalamus of rats with estradiol-induced polycystic ovarian disease. J Endocrin 127:2969-2976
39. Dondi D, Limonta P, Maggi R, Piva F (1992) Effects of ovarian hormones on brain opioid binding sites in castrated female rats. Am J Physiol 263:E507-E511
40. Quiñones-Jenab V, Jenab S, Ogawa S, Inturrisi C, Pfaff DW (1997) Estrogen regulation of mu-opioid receptor mRNA in the forebrain of female rats. Brain Res Mol Brain Res 47:134-138 (Pubitemid 27268268)
41. Broad KD, Kendrick KM, Sirinathsinghji DJ, Keverne EB (1993) Changes in pro-opiomelanocortin and pre-proenkephalin mRNA levels in the ovine brain during pregnancy, parturition and lactation and in response to oestrogen and progesterone. J Neuroendocrinol 5:711-719 (Pubitemid 24013377)
42. Eckersell CB, Popper P, Micevych PE (1993) Estrogen-induced alteration of mu-opioid receptor immunoreactivity in the medial preoptic nucleus and medial amygdala. Neurosci. 18:3967-3976 (Pubitemid 28225700)
43. Guido M, Romualdi D, Lanzone A (2006) Role of opioid antagonists in the treatment of women with glucoregulation abnormalities. Curr Pharm 12:1001-1012
44. Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR (2002) Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril 77:936-944 (Pubitemid 34497160)
45. Hadziomerovic D, Rabenbauer B, Wildt L (2006) Normalization of hyperinsulinemia by chronic opioid receptor blockade in hyperandrogenemic women. Fertil Steril 86:651-657 (Pubitemid 44307010)
46. Lanzone A, Apa R, Fulghesu AM, Cutillo G, Caruso A, Mancuso S (1993) Long-term naltrexone treatment normalizes the pituitary response to gonadotropin-releasing hormone in polycystic ovarian syndrome. Fertil Steril 59:734-737 (Pubitemid 23104170)
47. Stener-Victorin E, Jedel E, Mannerås L (2008) Acupuncture in polycystic ovary syndrome: current experimental and clinical evidence. J Neuroendocrinol 20:290-298 (Pubitemid 351280093)
48. Minoia P (2001) Sciorsci RL.Metabolic control through L calcium channel, PKC and opioid receptors modulation by an association of naloxone and calcium salts. Curr Drug Targets Immune Endocr Metabol Disord 1:131-137